Cytarabine Treatment of Herpes Simplex Encephalitis

Farris, William A.; Blaw, Michael E.

doi:10.1001/archneur.1972.00490140003002

Cited by 39 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IudR, which has been shown to inhibit HSV in vitro (116,124,200,207,231), has yielded promising results in the treatment of herpes encephalitis (18,44,160,165,254) and herpetic keratitis (5,53,61,261). Similar results have been obtained with ara-c both in vitro (78,193,207) and in the treatment of a variety of herpetic eruptions (109) including oral lesions (158) and herpes encephalitis (73,86,257). Of the two drugs, ara-c is slightly favored, because of the ease of administration and its reduced toxicity to the host (73, 109), even though it may synergistically act with HSV to effectuate increased chromosomal damage (192,193).…”

Section: Treatment Of Recurrent Hsvmentioning

confidence: 82%

The latent herpes simplex virus.

Docherty¹,

Chopan²

1974

Bacteriological Reviews

View full text Add to dashboard Cite

Section: Treatment Of Recurrent Hsvmentioning

confidence: 82%

The latent herpes simplex virus.

Docherty¹,

Chopan²

1974

Bacteriological Reviews

View full text Add to dashboard Cite

“…19 In this study it appeared to retard the development of histological le¬ sions produced by herpes simplex vi¬ rus, whereas idoxuridine appeared in¬ effective. Further study of the effect of cytarabine on viral titers in the brain is indicated.…”

Section: Commentmentioning

confidence: 56%

Experimental Herpes Simplex Encephalitis

Panitch¹,

Baringer²

1973

Arch Neurol

View full text Add to dashboard Cite

An experimentally induced herpes simplex virus encephalitis in rabbits was treated with either idoxuridine or cytarabine. The cerebral lesions produced in this model bore histologic and topographic similarities to those seen in humans. Treatment was begun after infection was established in nervous system tissue. In animals treated with idoxuridine there was neither clinical nor histological evidence of a therapeutic effect. Cytarabine initially ap-

show abstract

“…Apart from our partial report of case VOL. 3,1973 on May 11, 2018 by guest http://aac.asm.org/ Downloaded from 1 (6), we are aware of only one other case in the literature (10). In this case, marked clinical improvement was also temporarily related to Ara-C therapy.…”

Section: Discussionmentioning

confidence: 92%

Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients

Chow

Ronald

Fiala

et al. 1973

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Two neonates and four adults with herpes simplex virus (HSV) encephalitis were treated with cytosine arabinoside (Ara-C). A low dose of 40 to 160 mg per m 2 per day was given for 4 to 6 days by continuous intravenous infusion and, except in two cases, by intrathecal administration. In one patient, idoxuridine (IUdR) at the dose of 1 g every 4 h was also administered after 4 days of Ara-C therapy. Both neonates and two of four adults survived. Their clinical improvement was closely related in time to the onset of therapy with Ara-C (cases 1, 2, 3) and with IUdR (case 4). In one adult who died on the 27th day of illness of a massive pulmonary embolus, postmortem examination of the brain did not disclose viral inclusions, and viral culture was negative. In the other patient who died, however, brain culture postmortem was still positive for HSV despite 4 days of Ara-C therapy. Ara-C, in addition to IUdR, may be effective in HSV encephalitis treatment, but double-blind, controlled studies appear to be necessary with these agents.

show abstract

Cytarabine Treatment of Herpes Simplex Encephalitis

Cited by 39 publications

References 20 publications

The latent herpes simplex virus.

The latent herpes simplex virus.

Experimental Herpes Simplex Encephalitis

Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients

Contact Info

Product

Resources

About